- Home
- LSF vs ALGS Comparison
LSF vs ALGS Comparison
Compare LSF & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | ALGS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 43.0M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LSF | ALGS |
|---|---|---|
| Price | $2.47 | $7.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $46.67 |
| AVG Volume (30 Days) | ★ 34.2K | 31.3K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 75.28 | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,295,137.00 | $2,186,000.00 |
| Revenue This Year | $15.87 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.50 | N/A |
| 52 Week Low | $1.98 | $3.76 |
| 52 Week High | $7.94 | $13.69 |
Technical Indicators
Market Signals| Indicator | LSF | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 55.76 |
| Support Level | $2.41 | $7.61 |
| Resistance Level | $2.76 | $8.84 |
| Average True Range (ATR) | 0.19 | 0.56 |
| MACD | -0.02 | 0.15 |
| Stochastic Oscillator | 34.81 | 77.22 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.